评估COPD患者的炎症蛋白质生物标志物,有或没有α-1抗素缺乏症的患者
Matthew Moll1,2,3,4, Brian D Hobbs5, Katherine A Pratte6
1Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115.
medRxiv : the preprint server for health sciences
|January 27, 2025
概括
血液中的炎症性蛋白质生物标志物与阿尔法-1抗素缺乏症 (AATD) 患者的COPD风险有关. 这些发现突出了炎症.
科学领域:
- 肺病学和呼吸系统医学
- 蛋白质组学和生物标志物发现发现
- 遗传学和遗传修饰剂的使用
背景情况:
- 患有Pi*ZZ基因型的α-1抗素缺乏症 (AATD) 患者显示慢性阻塞性肺病 (COPD) 风险不同.
- 不吸烟的AATD个体发展COPD表明炎症过程独立于吸烟.
- 这项研究调查了炎症蛋白质生物标志物作为AATD中COPD的预测因素.
研究的目的:
- 在AATD患者中识别与COPD相关的血液蛋白质生物标志物.
- 探索炎症在AATD中COPD病变发生中的作用.
- 在AATD中开发和验证用于COPD预测的蛋白质组风险评分.
主要方法:
- 对COPDGene (Pi*MM) 和AAT基因修饰剂研究 (Pi*ZZ) 的参与者的分析.
- 识别与FEV1/FVC相关的蛋白质,以混因子和家族关系进行调整.
- 构建肺部特定的蛋白质-蛋白质相互作用网络,并开发蛋白质基因风险评分 (protRS).
主要成果:
- 已经确定了与空气流阻塞相关的16种血液蛋白,其中14种在肺部高度表达.
- 蛋白质与蛋白质相互作用网络涉及免疫系统调节和细胞因子信号传递.
- 蛋白质基因风险得分改善了AATD个体的COPD预测 (AUC为0.86与0.80).
结论:
- 与炎症过程相关的血液蛋白质预测了AATD中的空气流阻塞.
- 免疫激活和炎症是AATD中COPD风险的关键调节者.
- 像AGER这样的生物标志物是这一群体中COPD的重要预测因素.
相关概念视频
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:26COPD: Management Using Bronchodilators and Corticosteroids
174
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
174
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:30Pneumonia III: Complications and Assessment
151
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
151
01:20COPD: Pathogenesis and Clinical Features
228
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
228